KSU licenses technology that could lead to developing a drug to treat the coronavirus
Amid increasing worldwide concern about a novel coronavirus, COVID-19, Kansas State University has licensed a technology that may lead to the production of an antiviral drug to treat coronaviruses and noroviruses. The university has entered into an agreement with Cocrystal Pharma Inc., a clinical stage biotechnology company that is discovering and developing novel antiviral therapeutics to further develop certain proprietary broad-spectrum antiviral compounds for the treatment of norovirus and coronavirus infections. Read more here.
